In plain words
Three small trials gave people NMN for several weeks and found no change in liver blood tests. Three analyses that combined studies, which may include those same trials, disagree: two found no change and one found lower levels of one liver enzyme, ALT.
The short answer
The three randomized trials on this page all found no effect on liver tests: 1250 mg a day for up to 4 weeks in 31 people (Fukamizu, 2022), 250 mg a day for 12 weeks in 34 people (Katayoshi, 2023), and 250 mg a day for 12 weeks in older men, with no n in the ledger (Igarashi, 2022). Pooled estimates that may include these trials split: Chen (2024) and Yang (2026) found no difference, while Wang (2025) found lower ALT in 412 people, with no dose or duration in the ledger. Certainty is low, because the trials are small and short.
Where the evidence sits
Lower liver enzymes
No change in liver tests
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Fukamizu et al., 2022 | No liver damage | Randomized trial | 31 | 1250 mg a day, up to 4 weeks | Not in ledger |
| Igarashi et al., 2022 | Liver enzymes no different from placebo | Randomized, placebo-controlled | Healthy older men, n not in ledger | 250 mg a day, 12 weeks | Not in ledger |
| Katayoshi et al., 2023 | No change in blood chemistry | Randomized trial | 34 | 250 mg a day, 12 weeks | Not in ledger |
| Chen et al., 2024 | No difference in AST, ALT, ALP | Meta-analysis of 6 studies | Not in ledger | Not in ledger | Not in ledger |
| Wang et al., 2025 | Lower ALT | Meta-analysis | 412 | Not in ledger | Not in ledger |
| Yang et al., 2026 | No change in AST or ALT | Meta-analysis of 10 comparisons | 330 | Not in ledger | Not in ledger |
No liver damage
Liver enzymes no different from placebo
No change in blood chemistry
No difference in AST, ALT, ALP
Lower ALT
No change in AST or ALT
Did liver enzymes change in the trials?
Fukamizu and colleagues (2022) gave 31 people 1250 mg of NMN once a day for up to 4 weeks and looked for liver damage (hepatotoxicity). They concluded that NMN
can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing
Igarashi and colleagues (2022) gave healthy older men 250 mg a day or a placebo for 12 weeks; the ledger has no n for this trial. They compared the two groups:
No significant difference was observed between the NMN and placebo groups with respect to hematological and blood chemistry parameters, including liver enzymes and renal function markers
Katayoshi and colleagues (2023) found no significant change in blood chemistry in 34 people after 250 mg a day for 12 weeks.
Do the pooled analyses agree on ALT?
Three meta-analyses pooled NMN studies, and each may include the trials above, so none is an extra measurement. Chen and colleagues (2024) found no difference in the liver markers AST, ALT and ALP across 6 studies; the ledger has no n, dose or duration for them. Yang and colleagues (2026) pooled 10 comparisons in 330 people, with no dose or duration in the ledger for these figures:
NMN supplementation did not significantly alter ALT levels: MD = −1.03 U/L, 95% CI −2.51 to 0.44, p = 0.169, I2 = 0%.
Wang and colleagues (2025) reported lower ALT in a pooled estimate that may include the trials above, covering 412 middle-aged and older people, with no dose or duration in the ledger:
NMN had a better effect on ALT (SMD: -0.29 IU/L, 95%CI [-0.55, -0.03] p = 0.028).
Why the sources disagree
The three trials measured people directly and point one way; the split is among pooled estimates that may include those trials. Wang limited its pool to middle-aged and older people and reported a standardized difference, while Yang reported a raw difference in U/L. The trials differ in dose and length, from 250 mg a day for 12 weeks to 1250 mg a day for up to 4 weeks, in groups of 31 and 34 people plus older men with no n in the ledger. The ledger has no funding information for any of the six sources.
What would settle it
An independent, pre-registered randomized trial comparing NMN at 250 mg and 1250 mg a day with placebo for at least 24 weeks in middle-aged and older adults, with ALT, AST and ALP as primary outcomes reported as differences from placebo in U/L. A matching result from a second research group would raise certainty from low to moderate.
How this page was made
The 6 sources are three randomized trials and three meta-analyses, whose pooled estimates may include the trials above, found through a PubMed literature search and chosen because they report liver blood tests in people. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. "Leaning" means the independent trials point mostly one way; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 23 Sep 2026, first version, 6 sources.
